Molecular Med Tri-Con 2018 is one of the world’s leading international events in the field of drug discovery, development, and diagnostics. Please visit us at booth 824 to explore our state-of-the-art services that can support your research and development projects. Meet our specialists to discuss our tools for immuno-oncology research, such as fluorescent multiplex IHC, digital-image analysis, as well as isolation and flow-cytometry analysis of tumor-infiltrating lymphocytes. You can also learn how we can support you with specimen collection, genomics, proteomics, immunophenotyping, and more! From basic research to clinical trials, we’re here to assist you.
|Location:||The Moscone South Convention Center|
747 Howard Street
San Francisco, CA 94103
Please visit us at booth 824
It was our great pleasure to take part in the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting, held on November 8–12 in National Harbor, USA. Indivumed, in collaboration with OracleBio, presented a poster showcasing dual immunohistochemistry (IHC) and digital histopathology as one example of the powerful techniques we use to study tumor-infiltrating immune cells. We demonstrated that chromogenic dual IHC and digital quantification of CD3- and LAG-3-positive T cells in clinical samples serves as a useful tool for specific evaluation of immune cell relationships in the tumor microenvironment of NSCLC tissue.
Enter your details here to download the research study poster presentation.
Toward meeting your research needs, Indivumed is pleased to announce we have complemented our high-quality immunohistochemistry (IHC) services by offering Fluorescent Multiplex IHC with Tyramide Signal Amplification. With this service, up to six targets of interest can be analyzed on one tissue section. Tyramide Signal Amplification ensures the highest sensitivity in fully automated multiplex staining, and whole-slide scans, including seven fluorescent layers, allow complex digital image analyses and long-term storage.
September 19, 2017
Indivumed and Helomics partner to unlock the power of cancer biospecimens for drug discovery and development
Indivumed GmbH (Indivumed) and Helomics® Corporation (Helomics) announce their intentions to collaborate to analyze human cancer biospecimens and annotated clinical data from consenting patients around the world, enabling cutting-edge basic and translational research in cancer.Read More
August 02, 2017
MedStar Health will collaborate with Indivumed to advance our understanding of the molecular basis of cancer through collection and analysis of biospecimens and clinical data, making possible new individualized diagnosis and treatment of cancer.Read More
April 11, 2017
Hamburg's First Mayor, Olaf Scholz, and international guests from science and business honored Indivumed at its 15-year anniversary.Read More